
Participant flow



*Other reasons not eligible (n=80): Delayed reconstruction (n=33), Mastectomy only (19), WLE/BCS (17), Non-SSM (7), Latex allergy (3) and NSM (1). †Patient had SRM. ‡ Patients had NSM and mastectomy only. *If did not withdraw prior to surgery and provided data on compliance. *Follow-up for necrosis: day 0 up to 30-40 days if did not withdraw prior to surgery.

Baseline characteristics

	11.0 1.11			
Baseline characteristic	N Control/ N Heated	Control	Heated	Total
	70/71	Control	Пеацеи	IOlai
Age (years)	70/71	50 5 (0 2)	50 6 (0 5)	50 6 (0 A)
Mean (SD)		50.5 (9.3)	50.6 (9.5)	50.6 (9.4) 49.6 (44.7, 57.5)
Median (IQR) Height (metres)	70/71	49.7 (45.1, 54.9)	49.6 (44.1, 58.3)	49.6 (44.7, 57.5)
Mean, SD	70/71	1.6 (0.1)	1.6 (0.1)	1.6 (0.1)
Median, IQR		, ,		, ,
	70/71	1.6 (1.6, 1.7)	1.6 (1.6, 1.7)	1.6 (1.6, 1.7)
Weight (kilograms) Mean, SD	70/71	76 9 (14 0)	72 6 (14 0)	74 7 (14 1)
		76.8 (14.0)	72.6 (14.0)	74.7 (14.1)
Median, IQR	70/71	74.0 (66.8, 84.5)	71.0 (61.9, 83.8)	72.2 (64.0, 83.8)
BMI Mann CD	70/71	00.0 (5.0)	07.7 (5.4)	00.4 (5.0)
Mean, SD		28.6 (5.2)	27.7 (5.1)	28.1 (5.2)
Median, IQR	70/71	28.1 (24.7, 31.8)	27.0 (23.9, 30.5)	27.4 (24.4, 31.0)
Ethnicity (n, %)	70/71	47 (070/)	FO (700/)	00 (700/)
White		47 (67%)	52 (73%)	99 (70%)
Black		19 (27%)	13 (18%)	32 (23%)
Asian		1 (1%)	1 (1%)	2 (1%)
Mixed race		2 (3%)	3 (4%)	5 (4%)
Other	70/74	1 (1%)	2 (3%)	3 (2%)
Diabetic* (n, %)	70/71	4 (404)	4 (00()	5 (40()
Diabetic		1 (1%)	4 (6%)	5 (4%)
Not Diabetic	4/4	69 (99%)	67 (94%)	136 (96%)
Insulin dependent (n, %)	1/4			
Insulin dependent		0 (0%)	1 (25%)	1 (20%)
Non-insulin dependent		1 (100%)	3 (75%)	4 (80%)
Hypertensive (n, %)	70/71			
No		63 (90%)	63 (89%)	126 (89%)
Yes	70/74	7 (10%)	8 (11%)	15 (11%)
Smoker* (n, %)	70/71			
Smoking		8 (11%)	10 (14%)	18 (13%)
Not smoking		62 (89%)	61 (86%)	123 (87%)
Smoking history	6/9			
(cigarettes/day)		0.0 (0.0)	0.0 (5.4)	7.0 (4.0)
Mean, SD		6.0 (3.9)	8.0 (5.4)	7.2 (4.8)
Median, IQR	7/0	6.5 (2.0, 10.0)	10.0 (3.0, 10.0)	8.0 (2.0, 10.0)
Smoking history	7/9			
(packs/year) Mean, SD		8.6 (5.1)	13.8 (11.0)	11.5 (9.0)
Median, IQR		8.0 (5.0, 15.0)	11.0 (2.0, 23.0)	10.5 (3.5, 16.5)
	70/71	6.0 (5.0, 15.0)	11.0 (2.0, 23.0)	10.5 (5.5, 16.5)
BRCA carrier* (n, %)	70/71	40 (400/)	40 (400/)	06 (400/)
Carrier		13 (19%)	13 (18%)	26 (18%)
Not a Carrier	70/70	57 (81%)	58 (82%)	115 (82%)
Neoadjuvant therapy (n, %)	10/10	40 (600/)	EQ (760/)	101 (700/)
None		48 (69%)	53 (76%)	101 (72%)
Chemotherapy		16 (23%)	11 (16%)	27 (19%)
Radiotherapy		2 (3%)	2 (3%)	4 (3%)
Chemotherapy + radiotherapy		4 (6%)	4 (6%)	8 (6%)
Previous breast surgery on	70/71	T (070)	- (U/U)	J (070)
study breast (n, %)	. 5/11			
		55 (79%)	53 (75%)	108 (77%)
		, ,	` '	` '
No Yes		55 (79%) 15 (21%)	53 (75%) 18 (25%)	108 (77%) 33 (23%)

	N Control/			
Baseline characteristic	N Heated	Control	Heated	Total
Type of previous breast	15/18			
surgery (n, %)				
Augmentation		0 (0%)	1 (6%)	1 (3%)
Reduction		0 (0%)	2 (11%)	2 (6%)
Wide local excision		5 (33%)	6 (33%)	11 (33%)
Wide local excision +		,	,	,
radiotherapy		10 (67%)	9 (50%)	19 (58%)
Oncological reason for	70/71			
mastectomy				
No		12 (17%)	12 (17%)	24 (17%)
Yes		58 (83%)	59 (83%)	117 (83%)
Prophylactic reason for	70/71			
mastectomy				
No		58 (83%)	59 (83%)	117 (83%)
Yes		12 (17%)	12 (17%)	24 (17%)

^{*}minimisation variables. Note: percentages are rounded so might not always sum to 100%.

Outcome measures

Skin necrosis within 30-40 days post-surgery by treatment group

	N Control/		
Necrosis outcome	N heated	Control	Heated
Post-operative skin necrosis (n, %)	66*/68**	10 (0-0)	-0 (-10)
No		43 (65%)	50 (74%)
Yes	00/04	23 (35%)	18 (26%)
Depth of necrosis at first occurrence	62/64		
(n, %) A – none		44 (71%)	50 (78%)
B – colour change		11 (18%)	9 (14%)
C – partial thickness		7 (11%)	4 (6%)
D – full thickness		0 (0%)	1 (2%)
Area of necrosis at first occurrence		5 (5.75)	. (=,0)
Total area if necrosis present (mm²)	18/14		
Mean (SD)		1260.7 (1423.0)	1397.1 (1829.4)
Median (IQR)			700.0 (400.0,
		850.0 (100.0, 2700.0)	1300.0)
Mix, Max		2.0, 4500.0	200.0, 6900.0
By SKIN score	44/0		
Area of colour change (mm²)	11/9	000 0 (4.440.0)	4040 7 (0400 0)
Mean (SD) Median (IQR)		962.9 (1413.0)	1616.7 (2132.8) 700.0 (600.0,
Median (IQR)		300.0 (50.0, 1020.0)	1300.0 (600.0,
Mix, Max		2.0, 4500.0	250.0, 6900.0
Area of partial thickness (mm²)	7/4	2.0, 4000.0	200.0, 0000.0
Mean (SD)		1728.6 (1411.2)	1202.5 (1303.9)
Median (IQR)		,	730.0 (355.0,
· ,		1500.0 (250.0, 3300.0)	2050.0)
Mix, Max		50.0, 3400.0	250.0, 3100.0
Area of full thickness (mm²)	0/1		222.2 ()
Mean (SD)		-	200.0 (-)
Median (IQR)		-	-
Mix, Max Total area for all patients	61/64	-	-
(including area=0mm² for none)	01/04		
Mean (SD)		372.0 (953.8)	305.6 (1014.6)
Median (IQR)		0.0 (0.0, 50.0)	0.0 (0.0, 0.0)
Mix, Max		0.0, 4500.0	0.0, 6900.0
Maximum depth of necrosis over 30-40	62/64	,	,
day follow-up (n, %)			
A – none		44 (71%)	50 (78%)
B – colour change		10 (16%)	9 (14%)
C – partial thickness		6 (10%)	3 (5%)
D – full thickness Maximum area of necrosis over 30-40		2 (3%)	2 (3%)
day follow-up			
Total area if necrosis present (mm²)	18/14		
Mean (SD)		1288.4 (1432.8)	1397.1 (1829.4)
Median (IQR)		·	700.0 (400.0,
		850.0 (100.0, 2700.0)	1300.0)
Mix, Max		2.0, 4500.0	200.0, 6900.0

	N Control/		
Necrosis outcome	N heated	Control	Heated
By SKIN score			
Area of colour change (mm²)	11/9		
Mean (SD) Median (IQR)		1029.2 (1471.3)	1616.7 (2132.8) 700.0 (600.0,
, ,		485.0 (50.0, 1020.0)	1300.0)
Mix, Max		2.0, 4500.0	250.0, 6900.0
Area of partial thickness (mm ²)	7/4		
Mean (SD) Median (IQR)		1766.7 (1542.0)	1450.0 (1477.3) 1000.0 (250.0,
,		1800.0 (250.0, 3300.0)	3100.0)
Mix, Max		50.0, 3400.0	250.0, 3100.0
Area of full thickness (mm ²)	0/1		
Mean (SD)		- (-)	200.0 (-)
Median (IQR)		- (-)	- (-)
Mix, Max		-	-
Total area for all patients	61/64		
(including area=0mm² for none)			
Mean (SD)		380.2 (965.8)	305.6 (1014.6)
Median (IQR)		0.0 (0.0, 50.0)	0.0 (0.0, 0.0)
Mix, Max		0.0, 4500.0	0.0, 6900.0
Necrosis resolved/fully healed within	17/13		
30-40 day follow-up (n, %)			
No		8 (47%)	7 (54%)
Yes		9 (53%)	6 (46%)

^{*}Necrosis outcome missing for n=1 patient in control group who had SRM. The remaining n=3 control patients without the necrosis outcome withdrew prior to surgery ** Necrosis outcome missing for n=2 patients in heated group who had NSM or mastectomy only. The remaining n=1 heated patient without the necrosis outcome withdrew prior to surgery. All measurements reported here by primary clinical assessor.

Necrosis presence by minimisation variables

	Control		Heated	
	Necrosis (N=23)	None (N=43)	Necrosis (N=18)	None (N=50)
Minimisation variable	N (%)	N (%)	N (%)	N (%)
Smoking				
Yes	3 (13%)	4 (9%)	2 (3%)	7 (14%)
No	20 (87%)	39 (91%)	16 (20%)	43 (86%)
Diabetic	, ,	, ,	. ,	, ,
Yes	1 (4%)	0 (0%)	0 (1%)	4 (8%)
No	22 (96%)	43 (100%)	18 (22%)	46 (92%)
Type of reconstruction	, ,	,	, ,	, ,
İmplant	4 (17%)	9 (21%)	3 (4%)	10 (20%)
Autologous	19 (83%)	34 (79%)	15 (19%)	40 (80%)
BRCA carrier status	, ,	, ,	` ,	, ,
Yes	3 (13%)	10 (23%)	2 (3%)	9 (18%)
No	20 (87%)	33 (77%)	16 (20%)	41 (82%)

Note: percentages are rounded so might not always sum to 100%.

Adverse events

Event type	Control	Heated	Total
	no. events	no. events	no. events
	(no. patients)	(no. patients)	(no. patients)
AR	0 (0)	1 (1)	1 (1)
SAE	10 (7)	20 (15)	30 (22)
SAR	0 (0)	0 (0)	0 (0)
Complication			
Mastectomy Skin-flap	5	2	
necrosis (requiring			7
surgery)			
Infection	2	4	6
Haematoma	2	6	8
Re-do anastomosis	0	4	4
Flap failure	1	3	4
Burn	0	1	1

Number of patients shown in brackets as some patients had more than one safety event. AR – Adverse Reaction related to heating protocol, SAE – Serious Adverse Event not related to heating protocol, SAR – Serious adverse reaction related to heating protocol. Note: AE – Adverse events (not serious and not related to heating protocol) were not recorded in the PREHEAT database.